Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 6/20 | 0.35 |
| ▸ | DRD2 | P14416 | 2/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | LTA4H | P09960 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.30 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3385537 | 0.81 | LTA4H (0.37) | KCNH2LTA4HCHRM2CHRM4CHRM5 | |
| SCHEMBL3380030 | 0.77 | KCNH2 (0.40) | KCNH2LTA4HCHRM2CHRM4CHRM5 | |
| SCHEMBL3382441 | 0.72 | ROCK2 (0.35) | KCNH2LTA4HCHRM2CHRM4CHRM5 | |
| SCHEMBL3381575 | 0.70 | KCNH2 (0.40) | KCNH2OPRK1OPRM1 | |
| SCHEMBL13005866 | 0.69 | ALDH1A1 (0.38) | DRD2DRD3 | |
| SCHEMBL3381244 | 0.67 | — | — | |
| SCHEMBL3380014 | 0.66 | PARP2 (0.41) | KCNH2OPRK1 | |
| SCHEMBL13617491 | 0.64 | OPRM1 (0.41) | KCNH2LTA4HOPRK1OPRM1OPRD1 | |
| SCHEMBL3382937 | 0.64 | KCNH2 (0.47) | KCNH2OPRK1OPRM1OPRD1 | |
| SCHEMBL3384979 | 0.64 | PKM (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1896467-B1 | TRICYCLIC OPIOID MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-01 | — | — | EP | disclosed |
| US-20090275610-A1 | TRICYCLIC OPIOID MODULATORS | DECORTE BART | 2009-11-05 | — | — | US | disclosed |
| US-20090275610-A1 | TRICYCLIC OPIOID MODULATORS | DECORTE BART | 2009-11-05 | — | — | US | disclosed |
| US-20090275610-A1 | TRICYCLIC OPIOID MODULATORS | DECORTE BART | 2009-11-05 | — | — | US | disclosed |
| US-7582650-B2 | Tricyclic opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-09-01 | — | — | US | disclosed |
| US-7582650-B2 | Tricyclic opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-09-01 | — | — | US | disclosed |
| US-7582650-B2 | Tricyclic opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-09-01 | — | — | US | disclosed |
| EP-1896467-A2 | TRICYCLIC OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-12 | — | — | EP | disclosed |
| WO-2006138528-A2 | TRICYCLIC OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V (BE) | 2006-12-28 | — | — | WO | disclosed |
| US-20060287297-A1 | TRICYCLIC OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287297-A1 | TRICYCLIC OPIOID MODULATORS | OPRD1, OPRM1, OPRK1 | KCNH2 838/4885DRD2 371/4885DRD3 450/4885 |
| US-20090275610-A1 | TRICYCLIC OPIOID MODULATORS | OPRD1, OPRM1, OPRK1 | KCNH2 838/4885DRD2 371/4885DRD3 450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.